Chronic hepatitis B therapy
The ultimate goals of therapy for chronic hepatitis B (CHB) are to prevent disease progression and to prolong patient survival ( ). 1 -3 These goals can be achieved as long as HBV replication can be suppressed and sustained. Major clinical studies have demonstrated the role of viral replication in the pathogenesis and progression CHB. A large prospective cohort study from Taiwan has shown that elevated HBV DNA ( 10 copies/mL) and its persistence significantly increase the risk of cirrhosis, hepatocellular carcinoma (HCC) and death, ≥ 4 regardless of HBeAg status or baseline ALT levels( ). These data have been supported by several other similarly designed studies. 4 Furthermore, one randomized controlled clinical trial of lamivudine in CHB patients with advanced fibrosis or cirrhosis showed the benefit of antiviral therapy on disease progression ( ). However, the clinical benefit of reducing disease progression was limited in patients who 5 developed lamivudine resistance ( ). Histological improvement has been observed during treatment with lamivudine, adefovir, tenofovir 5 and entecavir, although the development of resistance had a negative impact on the histological improvement observed with lamivudine (6 ).
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Thus, a maintained long-term response to therapy or a sustained off-treatment response are necessary to prevent liver damage and hepatic decompensation and to delay the onset of the long-term complications of CHB such as hepatocellular carcinoma (HCC).
However, interferon therapy is associated with side effects and its efficacy is limited to a small proportion of highly selected patients ( ). 3
Resistance to NUCs
Resistance to NUCs is a major issue affecting long-term therapy with some of these agents. Cumulative annual incidences of resistance among nucleoside-na ve CHB patients are shown in the . The rate of drug resistance has decreased dramatically with the ï Another important consequence of drug resistance and the subsequent need for rescue therapy is the increased risk of development of multi-drug resistant HBV by sequential accumulation of resistance mutations on the same viral genome (
). This risk is particularly 20 -22 high for drugs with low barriers to resistance and with overlapping resistance profiles. In a second or third-line treatment setting, studies have demonstrated that entecavir is effective in patients with adefovir resistance and patients with prior lamivudine treatment who had not developed resistance, but not in patients with proven lamivudine resistance ( ). This emphasizes the impact of cross resistance (in this 23
case, between lamivudine and entecavir) on the outcome of rescue therapy. Tenofovir has also been shown to be effective in patients with lamivudine-resistance and an incomplete response to adefovir, but not necessarily in all patients with adefovir resistance ( ). Thus, these 24 studies demonstrate that inadequate management of resistant patients increases the risk of developing multi-drug resistance. It has also been shown that variant strains with single point mutations may also exhibit a multi-drug resistant phenotype ( ). 25
Treatment guidelines and resistance management
Improvement in the availability of better therapies and virological monitoring tools have led to a progressive change in treatment guideline recommendations. Besides lowering HBV DNA and ALT thresholds for treatment indications, international guidelines recommend that therapy be initiated with a potent antiviral with a high barrier to resistance, such as entecavir or tenofovir, to reach undetectable HBV DNA as a primary endpoint thus minimizing the risk of selecting resistant variants ( , ) ( ).
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Avoid unnecessary treatment
To further minimize the risk of resistance, unnecessary treatment should be avoided and HBV DNA should be carefully monitored to check for primary non-response (<1 log drop in HBV DNA at week 12) as well as partial response (detectable HBV DNA at week 24). 10 Treatment decisions for patients with partial response may be influenced by drug potency and barrier to resistance ( ). In patients treated 2 with lamivudine, adefovir or telbivudine with a partial response at week 24, treatment should be adapted with a switch to a more potent drug or the addition of a second drug with a non-overlapping cross-resistance profile. In patients treated with entecavir or tenofovir who have a partial response at week 48, some experts suggest adding the other drug ( ). Alternatively, as long as the decrease in viral load 2 continues, monotherapy can be continued because of the very low resistance rates. However, if there is no progressive continuous decline in viral load levels and a subsequent plateau occurs, then the regimen should be adapted, preferably with an add-on strategy. With such a strategy, the development of resistance can be prevented in most cases.
Avoid sequential monotherapy
Recommendations for the management of patients who develop antiviral resistance are consistent among treatment guidelines ( , , 2 3 ). One key principle is that sequential monotherapy should be avoided in mostcases. If initial monotherapy fails, a second drug with a 26
non-overlapping resistance profile should be added or a switch should be made to a more potent combination of drugs ( ). Most patients 12
in treatment failure can be controlled with this rescue strategy.
Mechanism of antiviral drug resistance and barrier to resistance 3 7 Antiviral drug resistance is a result of adaptive mutations within the HBV genome and reduces the susceptibility of a virus to the inhibitory effects of a drug. The barrier to resistance can be defined as the difficulty with which these resistance mutants are selected ( ). 12 Mutations in the viral genome develop at a high frequency during viral replication, resulting in a diverse population of viral variants in infected individuals. Although HBV has a DNA-based genome, its replication cycle relies on an error-prone reverse transcription process, with mutations occurring at an estimated rate of 10 substitutions per base, per cycle ( ). Thus, drug resistance mutations may preexist 4 − 27 in patients who have no previous exposure to antiviral therapy. However, the actual selection of resistance mutations, and hence a drug barrier to resistance, is also influenced by several factors related to the virus (the number of mutations required to confer resistance, and their effect on viral fitness), the drug (mainly its antiviral potency) and the patient (treatment compliance and pharmacodynamics of the drug).
Entecavir and tenofovir are the preferred first-line treatments
The low rates of resistance and reductions in resistance-associated complications are the major benefits of using nucleoside analogs with a high barrier to resistance. Furthermore, since most patients who initiate treatment for CHB therapy, especially HBeAg-negative patients, are likely to require long-term therapy, first-line therapies with a high barrier to resistance offer the greatest chance of successful long-term treatment. Highly potent CHB therapies with the lowest rates of resistance, such as entecavir or tenofovir, are therefore the preferred first-line NUC treatment options in recently updated guidelines ( , , ). resistance mutations that are present before treatment. Therefore, such results must be interpreted with caution when making treatment decisions. High levels of serum HBV DNA, ALT and elevated body-mass index have all been linked to increased rates of lamivudine resistance ( , ). Furthermore, as might be expected, prior treatment with NUCs has been shown to predict drug resistance ( ).
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On-treatment monitoring and treatment adaptation: HBV DNA at week 24
The roadmap concept includes an algorithm for monitoring HBV DNA levels at weeks 12 and 24, with strategies suggested for patient management based on virological responses at the time points and the genetic barrier of the drug being used ( , ). The roadmap 30 31 concept proposes that patients with a complete virological response at week 24 (undetectable HBV DNA by PCR) remain on treatment with regular monitoring while patients with an inadequate virological response ( 2,000 IU/mL at week 24) should receive additional ≥ therapy with a more potent drug. Treatment decisions in patients with a partial virological response ( 60 to <2,000 IU/mL at week 24), are ≥ based on potency and genetic barrier: patients receiving NUCs with a high genetic barrier can remain on treatment beyond 48 weeks, patients receiving a less potent NUC should continue treatment and be re-assessed at week 48, and patients receiving NUCs with a low genetic barrier should add on a more potent drug because of the high risk of resistance if treatment is not adapted ( ). In all cases patients 2 should be monitored regularly for virological breakthrough. The rationale for treatment decisions in the roadmap concept are based on predictors of response from studies of drugs with low resistance barriers (lamivudine, adefovir and telbivudine). These analyses demonstrate that patients with a profound early virological response during treatment with lamivudine ( ), adefovir, ( ) and telbivudine 32 8
( ) have a lower chance of developing resistance. However, because of the very low rates of resistance observed with entecavir and 16 tenofovir ( , ) it has not been possible to accurately assess predictors of resistance in these drugs. The main advantage of the roadmap 7 33
is that it provides a comprehensive guide to short-term monitoring in patients receiving first-line therapy with a drug that has a low barrier to resistance. However, the clinical outcomes associated with the roadmap concept have not been examined in a prospective study.
If this principle of treatment monitoring and adaptation is followed, most patients can be controlled, whether they start therapy with drugs with a high or low barrier to resistance.
Crucial role of treatment adherence
Poor adherence substantially reduces viral suppression and may increase resistance rates, as previously discussed. Good adherence to regimens with a low barrier to resistance is therefore absolutely necessary. Adherence may be monitored using patient reports, dispensed
Conclusions
Clinical studies have demonstrated that drugs with a high barrier to resistance, such as entecavir and potentially tenofovir, have significantly lower rates of resistance when compared to those with a low barrier to resistance such as lamivudine, adefovir or telbivudine.
The barrier to resistance of a drug can be defined as the difficulty with which antiviral resistance is selected during CHB therapy. This can be influenced by a number of factors including the drug s genetic barrier and intrinsic potency, the level of adherence to the treatment ' regimen, pharmacological barriers and the replication fitness of any drug-resistant variants that arise during viral replication.
Compelling evidence connects high levels of viral replication to an increased time to HBV DNA undetectability during treatment, and an increased incidence of cirrhosis, HCC and liver-related mortality. Thus, the correct choice of a first line potent therapy to achieve sustained long-term suppression of viral replication provides the best chance of achieving the goals of therapy, which are to prevent the progression of liver disease and to prolong survival. Most patients receiving treatment will require long-term therapy to meet these goals and the development of antiviral resistance is a major concern in these cases. Treatment with a potent drug that has a high barrier to resistance, such as entecavir or tenofovir, will minimize future resistance, preserve future treatment options, protect public health and maximize the chances of long-term treatment success. Furthermore, the correct choice of first-line therapy also provides the best chance of avoiding the need for salvage therapy, which can be significantly affected by NUC antagonism and cross-resistance. In recent years, results of studies and clinical experience have shown that major progress has been made in the management of antiviral drug resistance which has now become a manageable issue provided that adequate virological monitoring and treatment adaptation are performed. In developing countries where HBV infection is endemic programmes are needed for cost-effective delivery of the best drugs and virological monitoring, improving availability of antiviral treatment patient management and the prevention of resistance. 
Perspectives
Inhibition of cell entry
The inhibition of virus cell entry is one of these main targets ( , ). Administration of pre-S1 peptides mimicking the envelope 34 35 protein domain involved in virus/cell membrane interaction resulted in the prevention of virus entry in the hepatocyte culture and the inhibition of viral infection and spread in a humanized SCID mouse model. Theoretically, the combination of this peptide with NUCs should prevent the infection of new cells while viral load is being suppressed by NUCs, thus increasing the rate of clearance of infected cells. More experimental studies are required for a proof of concept to test this hypothesis in clinical trials.
Targeting cccDNA
Targeting the formation and subsequent processing of viral cccDNA would be the ideal target but currently no candidate drug without cytotoxic effects is available for experimental studies. Epigenetic regulation of cccDNA transcriptional activity is another possible target which needs to be further investigated in experimental models ( ). 36
Capsid formation
Viral pregenome encapsidation and capsid formation represent potential targets. Phenylpropenamide derivatives and heteroaryl-pyrimidines (HAP) have been studied in hepatoma cell lines and been shown to inhibit replication of both wild type and in vitro amivudine resistant mutant genomes ( ). Unfortunately the development of phenylpropenamides was not continued in the clinical 37 -40 setting because of toxicity. More recently AiCuris Pharmaceuticals has developed the HAP molecules as non-nucleoside inhibitors of HBV core protein dimerization, blocking nucleocapsid formation ( , ), and demonstrating efficacy in an animal model of HBV infection ( 39 40 ). 39
Other targets
Finally, viral morphogenesis and egress represent another potential target for inhibition of the viral life cycle. In this respect, it was shown that Iminosugars which modulate the glycosylation status and conformation of envelope proteins may decrease the production of infectious particles ( ), resulting in an antiviral effect in the woodchuck model of hepadnavirus infection ( ). in vitro 41 in vivo 42 dendritic cells ( ) or the stimulation of the specific adaptive immune response ( ) to induce a sustained immunological control of 44 45 -47 HBV infection to allow appropriately timed cessation of NUC administration. 
